Abstract:Background: Tumor mutational burden (TMB) is associated with genome instability and immunogenicity, which has been reported to play an important role in predicting the efficacy of immune checkpoint inhibitors. However, the relationship of TMB and prognosis in solid tumors is not yet fully understood. In this study, we aimed to explore the association between TMB and prognosis across pan-cancers.Table: 57PDThe associations of TMB and OS across pan-cancerstumorfull namesTMB-median (interquartile)ALLStage I-IIStage III-IVNHR(95% CI)PNHR(95% CI)PNHR(95% CI)PBLCABladder Urothelial Carcinoma151(85-269)4080.51(0.33-0.78)<0.0011311.07(0.45-2.55)0.892750.41(0.24-0.68)<0.001BRCABreast invasive carcinoma39(26-69)9701.48(0.87-2.54)0.157200.98(0.49-1.94)0.952294.46(1.57-12.69)<0.001CHOLCholangiocarcinoma32(26-44)411.37(0.35-5.32)0.65282.33(0.44-12.49)0.32(-)(-)(-)COADColon adenocarcinoma111(82-167)3781.43(0.79-2.58)0.242023.24(0.93-11.37)0.071651.57(0.7-3.5)0.27ESCAEsophageal carcinoma100(77-144)1831.84(0.98-3.48)0.06973.01(1.18-7.68)0.02631.07(0.36-3.14)0.90GBMGlioblastoma multiforme47(37-64)3851.01(0.73-1.42)0.93(-)(-)(-)(-)(-)(-)HNSCHead and Neck squamous cell carcinoma92(60-140)5061.65(1.11-2.45)0.01963.94(1.34-11.59)0.013411.11(0.69-1.78)0.66KIRCKidney renal clear cell carcinoma48(35-63)3333.72(1.79-7.75)<0.0012228.23(1.9-35.6)<0.0011091.82(0.75-4.38)0.18KIRPKidney renal papillary cell carcinoma54(35-73)2770.39(0.13-1.15)0.091871.17(0.19-7.04)0.8663(-)(-)LGGBrain Lower Grade Glioma25(18-34)5015.03(2.87-8.8)<0.001(-)(-)(-)(-)(-)(-)LIHCLiver hepatocellular carcinoma77(55-107)3571.5(0.88-2.53)0.132501.87(0.87-3.98)0.11861.36(0.61-3.05)0.45LUADLung adenocarcinoma171(74-338)5010.83(0.54-1.28)0.393900.89(0.52-1.52)0.671040.69(0.33-1.46)0.33LUSCLung squamous cell carcinoma205(148-297)4830.75(0.52-1.09)0.133900.7(0.46-1.06)0.09890.92(0.38-2.21)0.84OVOvarian serous cystadenocarcinoma79(53-130)4290.73(0.52-1.03)0.08(-)(-)(-)(-)(-)(-)PAADPancreatic adenocarcinoma35(25-46)1731.62(0.88-3.02)0.12(-)(-)(-)(-)(-)(-)READRectum adenocarcinoma95(74-127)1270.68(0.21-2.27)0.53611.22(0.11-13.47)0.87580.6(0.1-3.72)0.59SARCSarcoma40(27-54)2351.25(0.63-2.49)0.52(-)(-)(-)(-)(-)(-)SKCMSkin Cutaneous Melanoma226(62-415)1030.45(0.15-1.3)0.14670.14(0.01-1.32)0.09311.51(0.36-6.32)0.58STADStomach adenocarcinoma106(66-216)4090.52(0.34-0.8)<0.0011780.45(0.2-0.98)0.052140.53(0.31-0.92)0.02THCAThyroid carcinoma9(6-13)4886.92(0.85-56.28)0.07325(-)(-)1611.34(0.16-11.19)0.79UCECUterine Corpus Endometrial Carcinoma89(47-562)5270.27(0.13-0.57)<0.001(-)(-)(-)(-)(-)(-)UVMUveal Melanoma12(9-15)682.5(0.45-13.88)0.2937(-)(-)302.4(0.19-30.98)0.50 Open table in a new tab Methods: Whole-exome sequencing from 7882 solid tumors, spanning 22 cancer types from The Cancer Genome Atlas were analyzed. TMB was defined by total non-silent somatic mutation counts in coding region. Patients were classified into four groups based on the quartiles of TMB in each tumor. All Hazard ratios (HR) were reported as the risk ratio of the top 25% to the bottom 25% group. Results: Among 22 tumors, the level of TMB of top five tumors (median, interquartile, sample size) were: SKCM (226, 62-415, 103), LUSC (205, 148-297, 483), LUAD (171, 74-338, 501), BLCA (151, 85-269, 408), COAD (111, 82-167, 378). In all patient analyses of each tumor, higher TMB was associated with longer overall survival (OS) in BLCA, STAD and UCEC, and was associated with shorter OS in HNSC, KIRC and LGG. In stage I-II of each tumor, higher TMB was significantly associated with prolonged OS in STAD, but with shorter OS in ESCA, HNSC and KIRC. In stage III-IV of each tumor, higher TMB was significantly associated with prolonged OS in BLCA and STAD, but with shorter OS in BRCA. In 5 tumors (including BLCA, HNSC, KIRC, LUSC and THCA), patients with higher pathological stage had significantly higher TMB (P < 0.05). However, only in COAD and READ, patients with higher stage had significantly lower TMB (P < 0.05). Conclusions: Higher TMB played different roles in various tumors, which may be attribute to different driver mutations or other factors. Further analyses of underlying mechanism were underway to confirm and explore the potential prognosis prediction of TMB across pan-cancers. Legal entity responsible for the study: Feng Qiu. Funding: Has not received any funding. Disclosure: All authors have declared no conflicts of interest.

Multiomics Analysis of Tumor Mutational Burden Across Cancer Types

Tumor Mutation Burden Analysis in a 5,660 Cancer Patient Cohort Reveals Cancer Type-Specific Mechanisms for High Mutation Burden.

Identification of tumor mutation burden-associated molecular and clinical features in cancer by analyzing multi-omics data

Integrated Analysis of Tumor Mutation Burden and Immune Infiltrates in Hepatocellular Carcinoma

Multi-Level Analysis and Identification of Tumor Mutational Burden Genes across Cancer Types

Exploration of the role of tumor mutation burden in clinical significance, immunotherapy response predictor and immune cell infiltration in colon cancer

Tumor Mutational Burden is Associated with Poor Outcomes in Diffuse Glioma

Correlate tumor mutation burden with immune signatures in human cancers

57PDTumor mutational burden and prognosis across pan-cancers

Comprehensive analysis of TMB, TNB, and HLA via NGS sequencing in a large cohort of Chinese pan-cancer patients.

Multi-omics analysis of tumor mutation burden combined with immune infiltrates in melanoma

Blood Tumor Mutation Burden Can Predict the Clinical Response to Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer Patients

Multi-omics Analysis of Tumor Mutational Burden Combined with Prognostic Assessment in Epithelial Ovarian Cancer Based on TCGA Database.

Prognostic Role of Tumor Mutation Burden Combined With Immune Infiltrates in Skin Cutaneous Melanoma Based on Multi-Omics Analysis

Multi-omics analysis of tumor mutation burden combined with immune infiltrates in bladder urothelial carcinoma

Comprehensive Analysis of Tumour Mutational Burden and Its Clinical Significance in Prostate Cancer

Integrating Histologic and Genomic Characteristics to Predict Tumor Mutation Burden of Early-Stage Non-Small-Cell Lung Cancer

Analysis of tumor mutation burden combined with immune infiltrates in endometrial cancer

The correlations of tumor mutational burden among single-region tissue, multi-region tissues and blood in non-small cell lung cancer

The prognostic value of TMB and the relationship between TMB and immune infiltration in head and neck squamous cell carcinoma: A gene expression-based study

Pan-cancer Analysis of Tumor Mutational Burden and Homologous Recombination DNA Damage Repair Using Targeted Next-Generation Sequencing